Industry Leading TCR Pipeline Targeting Solid and Hematologic Cancers
Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.
SPEAR® T-cell therapies targeting NY-ESO, MAGE-A10, MAGE-A4 and AFP are progressing into and through clinical studies in multiple U.S. clinical sites. In addition, we have identified over 30 intracellular target peptides preferentially expressed in cancer cells and we are currently progressing 12 through un-partnered research programs.